- Home
- GITS vs CANF Comparison
GITS vs CANF Comparison
Compare GITS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | CANF |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | South Korea | Israel |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GITS | CANF |
|---|---|---|
| Price | $1.86 | $2.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 144.5K | 23.7K |
| Earning Date | 05-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.17 |
| 52 Week High | $7.09 | $10.40 |
Technical Indicators
Market Signals| Indicator | GITS | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 34.79 |
| Support Level | $1.27 | $0.55 |
| Resistance Level | $2.71 | $3.24 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 45.19 | 0.00 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.